Denmark: EU boosts Evaxion’s artificial intelligence vaccine research

The EIB has signed a €20 million loan agreement with Evaxion, supported by the Infectious Diseases Finance Facility window under the EU’s InnovFin – EU finance for innovators programme, backed by the EU’s research and innovation programme Horizon 2020, which guarantees EIB loans for highly innovative projects. The financing will support Evaxion’s research and development (R&D) investments in the use of artificial intelligence (AI) to determine the most suitable targets for immunotherapies for cancer and infectious diseases.

This is not a CAPTIS article. Originally, it was published here.